Deep mutational analysis reveals functional trade-offs in the sequences of EGFR autophosphorylation sites
- PMID: 30012625
- PMCID: PMC6077704
- DOI: 10.1073/pnas.1803598115
Deep mutational analysis reveals functional trade-offs in the sequences of EGFR autophosphorylation sites
Abstract
Upon activation, the epidermal growth factor receptor (EGFR) phosphorylates tyrosine residues in its cytoplasmic tail, which triggers the binding of Src homology 2 (SH2) and phosphotyrosine-binding (PTB) domains and initiates downstream signaling. The sequences flanking the tyrosine residues (referred to as "phosphosites") must be compatible with phosphorylation by the EGFR kinase domain and the recruitment of adapter proteins, while minimizing phosphorylation that would reduce the fidelity of signal transmission. To understand how phosphosite sequences encode these functions within a small set of residues, we carried out high-throughput mutational analysis of three phosphosite sequences in the EGFR tail. We used bacterial surface display of peptides coupled with deep sequencing to monitor phosphorylation efficiency and the binding of the SH2 and PTB domains of the adapter proteins Grb2 and Shc1, respectively. We found that the sequences of phosphosites in the EGFR tail are restricted to a subset of the range of sequences that can be phosphorylated efficiently by EGFR. Although efficient phosphorylation by EGFR can occur with either acidic or large hydrophobic residues at the -1 position with respect to the tyrosine, hydrophobic residues are generally excluded from this position in tail sequences. The mutational data suggest that this restriction results in weaker binding to adapter proteins but also disfavors phosphorylation by the cytoplasmic tyrosine kinases c-Src and c-Abl. Our results show how EGFR-family phosphosites achieve a trade-off between minimizing off-pathway phosphorylation and maintaining the ability to recruit the diverse complement of effectors required for downstream pathway activation.
Keywords: EGFR; SH2; deep mutational scanning; signaling; specificity.
Copyright © 2018 the Author(s). Published by PNAS.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
![Fig. 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6077704/bin/pnas.1803598115fig01.gif)
![Fig. 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6077704/bin/pnas.1803598115fig02.gif)
![Fig. 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6077704/bin/pnas.1803598115fig03.gif)
![Fig. 4.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6077704/bin/pnas.1803598115fig04.gif)
![Fig. 5.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6077704/bin/pnas.1803598115fig05.gif)
Similar articles
-
Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling.Biochem J. 2003 Dec 1;376(Pt 2):457-64. doi: 10.1042/BJ20030668. Biochem J. 2003. PMID: 14498832 Free PMC article.
-
Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling.EMBO J. 2001 Dec 3;20(23):6793-804. doi: 10.1093/emboj/20.23.6793. EMBO J. 2001. PMID: 11726515 Free PMC article.
-
The SH2-containing adapter protein GRB10 interacts with BCR-ABL.Oncogene. 1998 Aug 27;17(8):941-8. doi: 10.1038/sj.onc.1202024. Oncogene. 1998. PMID: 9747873
-
Shc phosphotyrosine-binding domain dominantly interacts with epidermal growth factor receptors and mediates Ras activation in intact cells.Mol Endocrinol. 1998 Apr;12(4):536-43. doi: 10.1210/mend.12.4.0094. Mol Endocrinol. 1998. PMID: 9544989
-
EGFR kinase possesses a broad specificity for ErbB phosphorylation sites, and ligand increases catalytic-centre activity without affecting substrate binding affinity.Biochem J. 2005 Dec 15;392(Pt 3):417-23. doi: 10.1042/BJ20051122. Biochem J. 2005. PMID: 16122376 Free PMC article.
Cited by
-
Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors.Chin J Cancer Res. 2024 Apr 30;36(2):124-137. doi: 10.21147/j.issn.1000-9604.2024.02.03. Chin J Cancer Res. 2024. PMID: 38751436 Free PMC article.
-
CX3CL1 (Fractalkine)-CX3CR1 Axis in Inflammation-Induced Angiogenesis and Tumorigenesis.Int J Mol Sci. 2024 Apr 25;25(9):4679. doi: 10.3390/ijms25094679. Int J Mol Sci. 2024. PMID: 38731899 Free PMC article. Review.
-
Distinct functional constraints driving conservation of the cofilin N-terminal regulatory tail.Nat Commun. 2024 Feb 16;15(1):1426. doi: 10.1038/s41467-024-45878-9. Nat Commun. 2024. PMID: 38365893 Free PMC article.
-
Stimulation of the catalytic activity of the tyrosine kinase Btk by the adaptor protein Grb2.Elife. 2023 Apr 26;12:e82676. doi: 10.7554/eLife.82676. Elife. 2023. PMID: 37159508 Free PMC article.
-
High-throughput profiling of sequence recognition by tyrosine kinases and SH2 domains using bacterial peptide display.Elife. 2023 Mar 16;12:e82345. doi: 10.7554/eLife.82345. Elife. 2023. PMID: 36927728 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous